Novel drug Delivery Systems (Unit:- 4) MCQs With Answers

1. Passive targeting is based on

1. a. Enhanced permeability
2. b. Retention
3. c. Mechanical disruption
4. d. All of the above

Ans: d

2. In nanoparticles the particle size / size distribution may be studied by

1. a. PCS
2. b.SEM
3. c.TEM
4. d. All of the above

Ans: d

3. Targeting drugs to specific organ is called

1. a. spatial placement
2. b. temporal delivery
3. c. both
4. d. none of the above

Ans: a

4. Ideal characteristics of targeted drug delivery system

1. a. Nontoxic and biodegradable
2. b. Biocompatible and physicochemically stable
3. c. Predictable and controllable rate of drug release
4. d. All of the above

Ans: d

5. The following characharictics is/are true for niosomes

1. a. Biocompatible
2. b. Non immunogenic
3. c. Biodegradable
4. d. All of the above

Ans: d

6. In physical targeting following characteristic is changed

1. a. Temperaturee
2. b. Light intensity
3. c. Electric field
4. d. All of the above

Ans: d

7. In nanoparticle technology, LDC stands for

1. a. Liquid drug concentration
2. b. Lyophilic drug conjugates
3. c. Lyophobic drug conjugates
4. d. Lipid drug conjugates

Ans: d

8. Niosomes are formulated by using ________ surface active agents

1. a. cationic
2. b. non-ionic
3. c. Anionic
4. d. zwitter-ionic

Ans: b

9. Size ranges for liposomes is

1. a) 25 to 5000 nm
2. b) 1 – 100 nm
3. c) 10 to 100 nm
4. d) >5000 nm

Ans: a

10. Advantages of solid lipid nanoparticles includes

1. a. Easy to scale-up and sterilize
2. b. Water based technology
3. c. More affordable
4. d. All of the above

Ans: d

11. Diameter of OLV is

1. a) 50 nm
2. b)100-1000nm
3. c)more than 1000nm
4. d)less than 100nm

Ans: b

12. Major components of niosomes preparation

1. a) Cholesterol
2. b) non-ionic surfactants
3. c) both a & b
4. d) ionic surfactants

Ans: c

13. Advantages of niosomes

1. a) They are osmotically active and stable
2. b) They increase the stability of the entrapped drug
3. c) Biodegradable,non immunogenic and bio compatible
4. d) All of the above

Ans: d

14. Organ Compartmentalization is following type of targeted delivery

1. a) First order targeting
2. b) Second order targeting
3. c) Third order targeting
4. d) None

Ans: a

15. Identify the odd one from the following,

1. a) Liposome
2. b) Reticuloendotyhelial system
3. c) Microsphere and nanoparticles
4. d) Monoclonal antibodies

Ans: b

16. The body’s natural immune system is used in which type of targeting

1. a) Active
2. b) Passive
3. c) Physical
4. d) Dual

Ans:b

17. Liposome, liquid particles and polymeric micelles belonging to which class of carrier

1. a) Soluble carrier
2. b) cellular carrier
3. c) particle carrier
4. d) none of the above

Ans: c

18. Important characteristics of in-vivo environment is

1. a) Size
2. b) Temperature
3. c) Density
4. d) Molecular weight

Ans: b

19. A monoclonal antibody(mAb or moAb) is an antibody made by cloning a unique__

1. a) RBC
2. b) Calcium
3. c) WBC
4. d) serum

Ans: c

20. Liposome contains oil soluble material in ___ cavity.

1. a) polar
2. b) hydrophilic
3. c) neutral
4. d) non polar

Ans: d

21. Liposome are spherical structure usually between _____ in diameter.

1. a) 80-100nm
2. b) 60-100nm
3. c) 55-100nm
4. d) 15-1000nm

Ans: d

22. Liposomes were discovered by

1. a) Alec Bangham
2. b) Handjani-vila
3. c) George E.palade
4. d) None of above

Ans: a

23. Controlling the rate of drug delivery to target site is called

1. a)Temporal Approach
2. b) Spatial Approach
3. c) Physical Approach
4. d)None of the above

Ans: a

24. The analytical techniques used in the characterization of cholesterol auto oxidation and anti oxidation degradation studies in Liposomes

1. a.) HPLC
2. b) TLC
3. c) GLC
4. d) Both a&b

Ans: d

25. The approach in which the carrier molecule has therapeutic activity and thus increase the therapeutic effect of drug is called

1. a) Dual targeting
2. b) Passive targeting
3. c) Double targeting
4. d) None of the above

Ans: a

26. The following can be include in physicochemical characterisation of nanoparticles

1. a) Reverse dialysis
2. b)surface properties
3. c)crystality
4. d)centrifugal ultrafiltration

Ans: c

27. Enhanced permeability and Retention is under which targeting approach

1. a) Active targeting
2. b) Passive targeting
3. c) Inverse targeting
4. d) None of the above

Ans: b

28. Liposomes have ——– half-life

1. a) Longer
2. b) Shorter
3. c) Intermediate
4. d) Both a & b

Ans: b

29. Nanomaterials differ significantly from other materials due to the following reason

1. a) Increased surface area
2. b) Quantum effects
3. C) Both a & b
4. d) None of the above

Ans : c

30. The main goal in designing nanoparticles as a delivery system

1. a)To control size and surface characteristics of particle
2. b)To achieve the site-specific action of the drug
3. c)Both a) and b)
4. d)None of the above

Ans : c

31. Chemical Characterization of Niosomes can be done by

1. a) Osmometer
2. b) LAL test
3. c) Electrophoresis
4. d) Zeta potential

Ans: a

32. One of the following is the disadvantage of liposomes

1. a. Biologically inert
2. b. Non antigenic
3. c. Embolism
4. d. Low elimination rate

Ans: c

33. Normal pH of the nasal secretion in adult is

• a) 5.5-6.5
• b) 3.5-4.5
• c) 6.5-7.5
• d) 2.5-3.5

Ans: a

34. Identify Monoclonal antibody associated with Alzheimer’s Disease

• a) Abciximab
• b) Alemtuzumab
• c) Aducanumab
• d) None of these.

Ans: c

35. The range of size of the colloidal particles used as nanoparticle is

1. a) 10-1000nm
2. b) 1-100nm
3. c) 100-10000nm
4. d) All of the above

Ans: a

36. The normal function of Reticulo Endothelial system is suppressed in

1. a) Active targeting
2. b) Passive targeting
3. c) Inverse targeting
4. d) Dual targeting

Ans: c

37. Non-ionic surfactant/s used to formulate niosomes

1. a. Tween-80
2. b. Cetrimide
3. c. Alkyl sulphates
4. d. All of the above

Ans: a

38. The terms FATMLV, SPLV, VET, DRV etc. are associated with

1. a. Niosomes
2. b. Liposomes
3. c. Ribosomes
4. d. Nanoparticles

Ans: b

39. In nano-particulate drug delivery, drug may be released by

1. a. Desorption of surface bound drug
2. b. Diffusion through the nanoparticle matrix
3. c. Matrix erosion
4. d. All of the above

Ans: d

40. Liposomes can trap as

1. a) Hydrophobic compounds
2. b)hydrophilic compounds
3. c) both a & b
4. d)none

Ans: c

41. Liposomes , lipid particles and polymeric mecellers belong to class of carrier

1. a. Soluble carriers
2. b. cellular carriers
3. c. Particle carriers
4. d. None of above

Ans: c

42. Example of liposome-based drug available in the market

1. a. Cifran OD
2. b.Lipodox
3. c. Paracip
4. d. Cytotec

Ans: b

43. Limitation of Nanoparticles

1. a.Particle-particle aggregation
2. b.Handling of nanoparticles difficult in liquid and dry forms.
3. c.Limited drug loading
4. d.All of the above

Ans: d

44. Identify Monoclonal antibody associated with Cancer treatment

1. a) Abciximab
2. b) Alemtuzumab
3. c) Aducanumab
4. d) None of these.

Ans: b

45. The rate at which monolithic devices transfer drugs to the patient body is proportional to_____of time.

1. a) Square of time
2. b) The square root of time
3. c) Twice the time
4. d) Half the time

Ans: b

46.Targeted drug delivery system should not be

1. a. Biochemically inert
2. b. chemically and physically stable in vivo and in vitro conditions
3. c. Biochemically toxic
4. d. Non immunogenic

Ans: d

47. Choose one of the following is NOT true

1. a) Modified release formulations are most useful for drugs with a long half-life
2. b) Modified release formulations can often reduce side-effects
3. c) Modified release formulations can improve patient compliance
4. d) Modified release formulation can be used for local drug delivery

Ans: a

48. The following methods are used for the purification of nanoparticles

1. a) Dialysis
2. b) gel filtration
3. c) ultra centrifugation
4. d) all of the above

Ans : d